Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Silo Pharma (SILO) EBT (2019 - 2025)

Silo Pharma (SILO) has disclosed EBT for 7 consecutive years, with -$881530.0 as the latest value for Q4 2025.

  • Quarterly EBT rose 49.06% to -$881530.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$4.2 million through Dec 2025, up 3.76% year-over-year, with the annual reading at -$4.2 million for FY2025, 3.76% up from the prior year.
  • EBT hit -$881530.0 in Q4 2025 for Silo Pharma, up from -$1.1 million in the prior quarter.
  • In the past five years, EBT ranged from a high of $6.5 million in Q3 2021 to a low of -$1.7 million in Q4 2024.
  • Historically, EBT has averaged -$598853.2 across 5 years, with a median of -$930296.5 in 2024.
  • Biggest YoY gain for EBT was 1266.57% in 2021; the steepest drop was 261.66% in 2021.
  • Year by year, EBT stood at -$1.1 million in 2021, then crashed by 57.31% to -$1.7 million in 2022, then surged by 36.76% to -$1.1 million in 2023, then plummeted by 64.57% to -$1.7 million in 2024, then skyrocketed by 49.06% to -$881530.0 in 2025.
  • Business Quant data shows EBT for SILO at -$881530.0 in Q4 2025, -$1.1 million in Q3 2025, and -$1.2 million in Q2 2025.